Related Experiment Video
Updated: Jun 22, 2025
09:17
Co-immunoprecipitation Assay Using Endogenous Nuclear Proteins from Cells Cultured Under Hypoxic Conditions
Published on: August 2, 2018
18.1K
Progress in Epigenetic Modification Regulating Drug Transporters in the Hypoxic Environment
Ziqin Wei1,2, Hongfang Mu1, Xiaojing Zhang1
1PLA Key Laboratory of the Plateau of the Environmental Damage Control, the 940th Hospital of Logistics Support Force of PLA, Lanzhou, 730050, China.
Current Drug Delivery
|June 28, 2024
Summary
Hypoxia significantly alters drug transporters via epigenetic modifications, impacting drug pharmacokinetics. Understanding these changes is crucial for safe high-altitude medication.
Area of Science:
- Pharmacology
- Molecular Biology
- Environmental Medicine
Background:
- Drug transporters critically influence drug pharmacokinetics, especially under hypoxic conditions.
- Hypoxia alters drug transporter expression through various regulatory pathways, including HIF-1, nuclear receptors, and inflammatory factors.
- Epigenetic modifications represent a key mechanism by which hypoxia regulates drug transporters, affecting ADME processes.
Purpose of the Study:
- To comprehensively review the effects of hypoxia on drug transporters and epigenetic modifications.
- To explore the regulatory mechanisms of epigenetic modifications on drug transporter expression under hypoxic conditions.
- To provide a reference for understanding epigenetic regulation of drug transporters at high altitudes and guide safe medication practices.
Main Methods:
- Literature review of studies on hypoxia, drug transporters, and epigenetic modifications.
- Analysis of regulatory pathways involving hypoxia-inducible factors (HIF-1), nuclear receptors, and inflammatory factors.
- Synthesis of current knowledge on epigenetic mechanisms (e.g., DNA methylation, histone modification) influencing transporter expression.
Main Results:
- Hypoxia induces significant changes in drug transporter levels and function.
- Epigenetic modifications are increasingly recognized as crucial regulators of drug transporters in hypoxic environments.
- High-altitude hypoxia presents unique challenges for drug pharmacokinetics due to altered transporter expression.
Conclusions:
- Epigenetic modifications play a vital role in mediating the effects of hypoxia on drug transporters.
- Further research into these epigenetic mechanisms is essential for optimizing drug therapy in hypoxic conditions, particularly at high altitudes.
- Understanding these interactions will facilitate the development of safer and more effective medication strategies for high-altitude populations.
Related Concept Videos
01:37Epigenetic Regulation
3.0K
Epigenetic changes alter the physical structure of the DNA without changing the genetic sequence and often regulate whether genes are turned on or off. This regulation ensures that each cell produces only proteins necessary for its function. For example, proteins that promote bone growth are not produced in muscle cells. Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
X-chromosome...
X-chromosome...
3.0K
01:06Carrier-Mediated Transport
335
Carrier-mediated transport is a pivotal process in drug absorption, particularly for lipid-insoluble drugs, and encompasses facilitated diffusion and active transport. Facilitated diffusion allows drugs to move along their concentration gradient without energy expenditure, while active transport utilizes ATP to drive drug movement against this gradient.
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
335
01:27Nonlinear Pharmacokinetics: Role of Transporters
47
A drug's nonlinear kinetics can be influenced by a diverse range of transporter proteins that serve as crucial players in drug distribution. These transporters, found within cells, can enhance or reduce local drug concentrations by facilitating the influx or efflux of drugs. For instance, the expression of xenobiotic transporters can be influenced by factors such as age and gender, potentially impacting the linearity of drug response.
Polymorphisms occurring in drug transporters can alter...
Polymorphisms occurring in drug transporters can alter...
47
01:16Drug Biotransformation: Overview
2.4K
Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...
2.4K
01:14Hepatic Drug Clearance: Role of Transporters
54
In the liver and bile canaliculi, influx and efflux transporters modification can influence intrinsic clearance. Transporters play a significant role in moving drugs within liver cells. Elaborate models, such as the Biopharmaceutical Classification System (BCS), are essential to relate transporters to drug disposition. This system categorizes drugs into four classes based on solubility and permeability, providing insights into elimination routes and the effects of transporters following oral...
54
01:07Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
38
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
A recent model describes pravastatin's hepatobiliary excretion,...
38